103.5K XNAS Volume
XNAS 31 Mar, 2025 1:27 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| James McArthur | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 60,719 | 62,413 | - | 0 | Common Stock | |
| James McArthur | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 271,875 | 271,875 | - | - | Stock Option (Right to Buy) | |
| Noel Donnelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 104,250 | 104,250 | - | - | Stock Option (Right to Buy) | |
| Noel Donnelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 23,283 | 24,956 | - | 0 | Common Stock | |
| Mary Beth DeLena | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 13,400 | 14,968 | - | 0 | Common Stock | |
| Mary Beth DeLena | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Noel Donnelly | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.68 per share. | 24 Feb 2025 | 1,527 | 1,673 | - | 1.7 | 2,565 | Common Stock |
| Noel Donnelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 3,200 | 3,200 | - | 0 | Common Stock | |
| Mary Beth DeLena | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 3,000 | 3,000 | - | 0 | Common Stock | |
| Mary Beth DeLena | General Counsel | Sale of securities on an exchange or to another person at price $ 1.68 per share. | 24 Feb 2025 | 1,432 | 1,568 | - | 1.7 | 2,406 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 24 Jul 2024 | 201 | 201 | - | 10.2 | 2,052 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2024 | 7,571 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2024 | 201 | 57,571 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.06 per share. | 24 Jul 2024 | 7,571 | 0 | - | 18.1 | 136,741 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 24 Jul 2024 | 7,571 | 7,571 | - | 10.2 | 77,300 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 24 Jul 2024 | 201 | 0 | - | 18.0 | 3,619 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 18 Jul 2024 | 12,625 | 12,625 | - | 10.2 | 128,901 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2024 | 12,625 | 57,772 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.20 per share. | 18 Jul 2024 | 12,625 | 0 | - | 18.2 | 229,804 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 12 Jul 2024 | 3,288 | 3,288 | - | 10.2 | 33,570 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 5,901 | 70,397 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 3,288 | 76,298 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 12 Jul 2024 | 5,901 | 0 | - | 18.0 | 106,247 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 12 Jul 2024 | 5,901 | 5,901 | - | 10.2 | 60,249 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.04 per share. | 12 Jul 2024 | 3,288 | 0 | - | 18.0 | 59,331 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.22 per share. | 01 Jul 2024 | 37 | 37 | - | 10.2 | 378 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 01 Jul 2024 | 875 | 0 | - | 18.0 | 15,760 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 01 Jul 2024 | 875 | 875 | - | 10.2 | 8,934 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 37 | 79,586 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 875 | 79,623 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.08 per share. | 01 Jul 2024 | 37 | 0 | - | 18.1 | 669 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 9,260 | 80,498 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.19 per share. | 24 Jun 2024 | 9,260 | 0 | - | 18.2 | 168,427 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 24 Jun 2024 | 9,260 | 9,260 | - | 10.2 | 94,545 | Common Stock |
| Laurie B. Keating | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Heidi Henson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Joshua Resnick | Director | 20 Jun 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | ||
| Habib Joseph Dable | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Howard Mayer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 8,667 | 8,667 | - | - | Stock Option (Right to Buy) | |
| Christopher Ashton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2024 | 1,086 | 89,758 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2024 | 500 | 90,844 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.06 per share. | 11 Jun 2024 | 1,086 | 0 | - | 18.1 | 19,615 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 11 Jun 2024 | 500 | 500 | - | 10.2 | 5,105 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 11 Jun 2024 | 1,086 | 1,086 | - | 10.2 | 11,088 | Common Stock |
| Michelle L. Mellion | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.04 per share. | 11 Jun 2024 | 500 | 0 | - | 18.0 | 9,022 | Common Stock |
| Michelle L. Mellion | SVP, Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 1,411 | 91,344 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | SVP, Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 05 Jun 2024 | 7,245 | 7,245 | - | 10.2 | 73,971 | Common Stock |
| Michelle L. Mellion | SVP, Clinical Development | Sale of securities on an exchange or to another person at price $ 18.09 per share. | 05 Jun 2024 | 7,245 | 0 | - | 18.1 | 131,062 | Common Stock |
| Michelle L. Mellion | SVP, Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.21 per share. | 05 Jun 2024 | 1,411 | 1,411 | - | 10.2 | 14,406 | Common Stock |
| Michelle L. Mellion | SVP, Clinical Development | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 05 Jun 2024 | 1,411 | 0 | - | 18 | 25,398 | Common Stock |
| Michelle L. Mellion | SVP, Clinical Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 7,245 | 92,755 | - | - | Stock Option (Right to Buy) | |
| Niels Svenstrup | SVP, Chem. Mfg & Controls | Sale of securities on an exchange or to another person at price $ 13.41 per share. | 17 May 2024 | 10,000 | 0 | - | 13.4 | 134,100 | Common Stock |
| James McArthur | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Noel Donnelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 144,000 | 144,000 | - | - | Stock Option (Right to Buy) | |
| Niels Svenstrup | SVP, Chem. Mfg & Controls | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 83,000 | 83,000 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 83,000 | 83,000 | - | - | Stock Option (Right to Buy) | |
| Mary DeLena Beth | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| McArthur James | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 4.17 per share. | 30 Nov 2023 | 1,694 | 1,694 | - | 4.2 | 7,056 | Common Stock |
| Mayer Howard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Nov 2023 | 22,686 | 22,686 | - | - | Stock Option (Right to Buy) | |
| Laurie B. Keating | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Heidi Henson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Joshua Resnick | Director | 22 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | ||
| Habib J. Dable | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Ashton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| James McArthur | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.04 per share. | 08 Jun 2023 | 2,381 | 0 | - | 16.0 | 38,188 | Common Stock |
| James McArthur | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 2,381 | 325,054 | - | - | Stock Option (Right to Buy) | |
| James McArthur | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.71 per share. | 08 Jun 2023 | 2,381 | 2,381 | - | 2.7 | 6,453 | Common Stock |
| James McArthur | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.18 per share. | 06 Jun 2023 | 18,150 | 0 | - | 16.2 | 293,660 | Common Stock |
| James McArthur | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2023 | 8,419 | 327,435 | - | - | Stock Option (Right to Buy) | |
| James McArthur | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2023 | 18,150 | 335,854 | - | - | Stock Option (Right to Buy) | |
| James McArthur | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.23 per share. | 06 Jun 2023 | 8,419 | 0 | - | 16.2 | 136,618 | Common Stock |
| James McArthur | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.71 per share. | 06 Jun 2023 | 8,419 | 8,419 | - | 2.7 | 22,815 | Common Stock |
| James McArthur | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.71 per share. | 06 Jun 2023 | 18,150 | 18,150 | - | 2.7 | 49,187 | Common Stock |
| James McArthur | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.04 per share. | 02 Jun 2023 | 1,800 | 0 | - | 16.0 | 28,863 | Common Stock |
| James McArthur | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.71 per share. | 02 Jun 2023 | 1,800 | 1,800 | - | 2.7 | 4,878 | Common Stock |
| James McArthur | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.71 per share. | 02 Jun 2023 | 500 | 500 | - | 2.7 | 1,355 | Common Stock |
| James McArthur | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.06 per share. | 02 Jun 2023 | 500 | 0 | - | 16.1 | 8,028 | Common Stock |
| James McArthur | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2023 | 1,800 | 354,504 | - | - | Stock Option (Right to Buy) | |
| James McArthur | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2023 | 500 | 354,004 | - | - | Stock Option (Right to Buy) | |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.88 per share. | 24 Mar 2023 | 392 | 392 | - | 10.9 | 4,265 | Common Stock |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2023 | 392 | 143,804 | - | - | Stock Option (Right to Buy) | |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 24 Mar 2023 | 392 | 0 | - | 20 | 7,840 | Common Stock |
| James McArthur | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Noel Donnelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 144,000 | 144,000 | - | - | Stock Option (Right to Buy) | |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Niels Svenstrup | SVP, Chem. Mfg & Controls | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 20,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | SVP, Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.88 per share. | 06 Feb 2023 | 1,677 | 1,677 | - | 10.9 | 18,246 | Common Stock |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Sale of securities on an exchange or to another person at price $ 17.18 per share. | 06 Feb 2023 | 3,679 | 0 | - | 17.2 | 63,213 | Common Stock |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.88 per share. | 06 Feb 2023 | 3,679 | 3,679 | - | 10.9 | 40,028 | Common Stock |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 06 Feb 2023 | 1,677 | 0 | - | 17.0 | 28,568 | Common Stock |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 644 | 144,196 | - | - | Stock Option (Right to Buy) | |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 3,679 | 144,840 | - | - | Stock Option (Right to Buy) | |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 1,677 | 148,519 | - | - | Stock Option (Right to Buy) | |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 06 Feb 2023 | 644 | 0 | - | 17 | 10,948 | Common Stock |
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.88 per share. | 06 Feb 2023 | 644 | 644 | - | 10.9 | 7,007 | Common Stock |
| Niels Svenstrup | SVP, Chem. Mfg & Controls | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2022 | 10,000 | 25,629 | - | - | Stock Option (Right to Buy) | |
| Niels Svenstrup | SVP, Chem. Mfg & Controls | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.71 per share. | 19 Dec 2022 | 10,000 | 10,000 | - | 2.7 | 27,100 | Common Stock |
| Habib J. Dable | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 22,686 | 22,686 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Laurie B. Keating | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 5,833 | 5,833 | - | - | Stock Option (Right to Buy) | |
| Laurie B. Keating | Director | Purchase of securities on an exchange or from another person at price $ 12.00 per share. | 06 May 2022 | 4,166 | 4,166 | - | 12 | 49,992 | Common Stock |
| Heidi Henson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 11,667 | 11,667 | - | - | Stock Option (Right to Buy) | |
| Joshua Resnick | Director | 06 May 2022 | 11,667 | 11,667 | - | - | Stock Option (Right to Buy) | ||
| James McArthur | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 466,095 | 466,095 | - | - | Stock Option (Right to Buy) | |
| Noel Donnelly | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 169,037 | 169,037 | - | - | Stock Option (Right to Buy) | |
| Jaya Goyal | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 79,920 | 79,920 | - | - | Stock Option (Right to Buy) | |
| Niels Svenstrup | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 109,874 | 109,874 | - | - | Stock Option (Right to Buy) | |
| Sonia Bracegirdle | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 79,547 | 79,547 | - | - | Stock Option (Right to Buy) | |
| Michelle L. Mellion | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 16,655 | 16,655 | - | - | Stock Option (Right to Buy) |